EQA for PD-L1 IHC staining: is it a conundrum? Keith Miller
|
|
- Gwendoline Neal
- 5 years ago
- Views:
Transcription
1 EQA for PD-L1 IHC staining: is it a conundrum? Keith Miller Director UK National External Quality Assessment Scheme for Immunohistochemistry & In-situ Hybridisation
2 The dangers of using laboratory developed tests as a CDx and especially in an NSCLC setting Keith Miller Director UK National External Quality Assessment Scheme for Immunohistochemistry & In-situ Hybridisation
3 New Host for the UKNEQAS-ICC&ISH Bart s HEALTH NHS Trust External Quality Assessment Services for Cancer Diagnostics - Community Interest Company not for profit
4 Professor Peter Isaacson Fellow of the Royal Society of Medicine 2009 Others who are Fellows of the Royal Society in London include Charles Darwin, Louis Pasteur
5 The UK National External Quality Assessment Scheme for Immunocytochemistry and ISH Fully Accredited under ISO UKNEQAS.org.uk
6 Strict Code of Practice Not for Profit Commercially neutral Monitor poor performance and assisting laboratories UK NEQAS central services are a registered charity
7 Breast HER2 IHC
8 Yesterday s Immunohistochemistry Laboratory k.miller@ucl.ac.uk
9 Range of HER2 immunostaining Negative Equivocal Positive FISH analysis
10 HER2 FISH Chr 17 centromere,, HER2. Ratio HER2:Chr is considered positive (20 60 non-overlapping nuclei assessed) 1.8 < 2.0 borderline negative 2.0 < 2.2 borderline positive
11 Breast Cancer Module: HER-2 Two diagnostic techniques AND two UK NEQAS EQA modules: IHC: Cell surface HER-2 protein expression Subjective scoring criteria 0 No staining / very slight partial membrane staining, < 10% of tumour cells 1+ Faint barely perceptible partial membrane staining, >10% of tumour cells 2+ Weak - moderate complete membrane staining, > 10% of tumour cells 3+ Strong complete membrane staining, > 10% of tumour cells FISH: Gene expression
12 Each of the cell lines for HER-2 have different levels of expression They are grown and processed to paraffinwax under very strict conditions The thickness of each section is measured with an interferometer UKNEQAS.org.uk
13 External EQA helps improve procedures over time HER2 IHC example UK laboratory Pass Rates:
14 The IHC Instruments available today All can also support either FISH or Chromogenic ISH protocols too
15 100% 90% 80% 70% Breast HER2 IHC: Kit v Laboratory Developed Test (HB) OS & UK ( combined data) % Users % Pass rate 92% UK 70% OS P< % P< % 100% 90% 80% 70% 60% 50% 53% 47% 60% 50% 40% 38% 40% 30% 20% Users of Approved CDx Users of LDTs Users of Approved CDx 30% 20% 10% 0% Kit-OS (n=2,483) HB-OS (n=1,574) Kit-UK (n=1,297) HB-UK (n=130) 8% Users of LDTs 10% 0%
16 ALK in NSCLC Detected in tumour specimens using: Immunohistochemistry (IHC) With positive cases confirmed by Fluorescence in situ hybridization (FISH) Reverse transcription polymerase chain reaction of cdna (RT-PCR) or NGS
17 UK NEQAS EQA for ALK includes cell lines and patient cancers
18 ALK Immunohistochemistry in Non-Small Cell Lung Carcinoma (NSCLC): A. Lessons Learned From External Quality Control OR B. Discordant Staining and Potential Impact On Patient Treatment Regimen C. Discordant Staining Can Impact Patient Treatment Regimen Merdol Ibrahim 1*, Suzanne Parry 1, Dawn Wilkinson 1, Neil Bilbe 1, David Allen 2, Steven Forrest 3, Perry Maxwell 5, Anthony O Grady 6, Jane Starczynski 7, Phillipe Taniere 1, John Gosney 3, Keith Kerr 1, Keith Miller 1 & Erik Thunnissen 9 1 UK NEQAS ICC & SH, Research Department of Pathology, University College London, London UK 2 UCLAD, Research Department of Pathology, University College London, London UK 3 Royal Liverpool University Hospital, Liverpool, UK 4 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands 5 Royal Victoria Hospital, Northern Ireland, UK 6 Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland 7 Birmingham Heartlands Hospital, Birmingham, UK 8 Queen Elizabeth Hospital, Birmingham, UK 9 Aberdeen Royal Infirmary, Aberdeen, Scotland Journal of Thoracic Oncology: July 2016
19 Average Pass Rates for ALK IHC
20 Dochotomous ALK-IHC is a better Predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer van der Wekken A, Pelgrim R, 't Hart N, et al. Clinical Cancer Research 2017 Feb 9. Main points: Results: Twenty-nine consecutive patients with ALK-positive advanced NSCLC diagnosed by FISH and/or IHC on small biopsies or fine needle aspirations (FNA) were treated with ALK inhibitors (Crizotinib). All ALK-IHC-positive patients responded to crizotinib except three with primary resistance. No tumor response was observed in 13 ALK-FISH-positive but ALK-IHC-negative patients This was confirmed in an external cohort of 16 patients. ROC curves for ALK- IHC and ALK-FISH compared to treatment outcome, showed that dichotomous ALK- IHC outperforms ALK-FISH
21 SP142 22C off-label use of Pharm-Dx! SP263 SP142 Pharm-Dx SP C3 CD, Poundbury Cancer Inst. Blueprint studies German harmonisation studies LDTs (laboratory developed tests)
22 PD-L1 CDx Landscape Ventana (SP142) Ventana (SP263) Dako (28-8) Dako (22C3) Type Rabbit Monoclonal Rabbit Monoclonal Rabbit Monoclonal Rabbit Monoclonal Commercial Availability CE IVD analytical claim CE-IVD predictive claim CE IVD predictive claim CE IVD predictive claim, CDx Pharma Partner Roche / Genentech AstraZeneca / MedImmune BMS Merck Pharma Drug name Atezolizumab Durvalumab Nivolumab Nivolumab Pembrolizumab CDx Configuration BenchMark Series RTU Antibody OptiView Detection OptiView Amp Complementary Dx BenchMark Series RTU Antibody OptiView Detection Complementary Dx Dako Autostainer Dako Link RTU antibody Complementary Dx Dako Autostainer Dako Link RTU antibody Companion Dx PD-1/PD-L1: the target of many drug
23 EQA for PD-L1 Technical PD-L1 Interpretive A mixture of appropriate tissues and cell lines that cover the main decision points within each of the respective assays.
24 PD-L1: Some of our assessors
25 PD-L1 Protocols/Antibodies employed by our participants At least 50% of participants are using laboratory developed tests
26 PD-L1 EQA on lung cancer & cell lines PD-L1 IHC -Dako Approved 22C3/28.8 CDx PD-L1 IHC - Ventana Approved SP263 CDx
27 Differences between the different assays for PD-L1 Roche-Ventana SP142 Roche-Ventana SP263 Dako 28-8 Dako 22C3
28 Scores for Clones SP263/22C3/28.8
29 Scores for Clones SP263/22C3/28.8
30 PD-L1 Laboratory Developed Test where there was a significant reduction of positive cells in all samples Seen with both SP263 and 22C3 antibodies
31 PD-L1: Approved v LDT Approved PD-L1 IHC CDx using SP263 on strong expressing cell line. 80%-100% of cells are positive Laboratory Developed Test using SP263 on strong expressing cell line. <20% of cells are positive
32 PD-L1: Approved v LDT Approved CDx using SP263 on Tonsil Laboratory developed test for SP263 on Tonsil
33 RTD Multiplexing Capabilities in Lung Esteban Roberts, Adrian Murillo, Teresa Ruffalo and Larry Morrison All images shown in this presentation are meant to serve as examples of the capability of the technology and are not to be interpreted as a medical claim or source of medical information
34 Interpretive EQA for PD-L1 PD1/PD-L1 An online service is being planned
35 PD-L1 Creating a digital slide resource for all EQA s across the world to access for their local Educational EQA activities
36 PD-L1 Digital Education Resource Pilot EQA provider Academia Academia EQA provider EQA provider IQN-Path Digital Resource +Ad Board Journal Publication Industry Industry
37 IQN-Path Digital Education Resource Working Group Keith Miller UK-NEQAS Chair Colin Tristram - Histiocyte John Garratt ciqc Jacqueline Hall (IQN Path) Working Group Committee Members Hans Juergen Grote (Merck), Els Dequeker (ESP EQA), Erik Thunissen (ESP EQA), Julia Pagliuso (RCPAQAP), Rudy Hovelinck (Astra Zeneca), Mogens Vyberg (NordiQC), Soren Nielsen (NordiQC), Robert Lott (Roche), Beth Sheppard (Roche), Zenobia Haffajee (RCPAQAP), Jessica Whiteley (RCPAQAP), Helle Fisker (Visiopharm), Daniel Martinez (SEAP). Manfred Dietel (QUIP), Colin Tristram (Histocyte), Xueying Shi s (CCP)
38 Digital Education Resource from IQN-Path STAGE 1 DEVELOPMENT STAGE 2 PD-L1 PILOT STAGE 3 FULL IMPLEMENTATION
39 Is this slide positive for Red Marbles?
40 What is the Percentage of Red Marbles?
41 Teaching and Training A unique combination in a single building: A dedicated independent slide-based Cancer Testing Laboratory An Education Centre for the pathology community Based at: The Poundbury Cancer Institute, Newborough House, Queen Mother Square, Poundbury, Dorset, UK
42 Advanced Course for Pathologists and Scientists at Poundbury Professor Keith Kerr giving a seminar on Lung Cancer Is this something for IQNPath to get Involved in?
43 And finally to our PD-L1/PD1 IHC Trainer!
44 Another successful PD-L1 trainee!
45 ACKNOWLEDGEMENTS Dr Merdol Ibrahim Suzanne Parry Neil Bilbe Ailin Rhodes Clara Lynch Dawn Wilkinson Seema Dhanjal Professor Bharat Jasani Dr Corrado D Arrigo Dr Sarah Wedden & John Garratt from CIQC David Allen Josep Linares Numerous assessors Roche-Ventana Menarini Visiopharm and many more k.miller@ucl.ac.uk
21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient
A meeting hosted by UK NEQAS ICC & ISH at The Tower Hotel Conference Centre St Katharine's Way, London E1W 1LD 21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient
More information21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient
A meeting hosted by at The Tower Hotel Conference Centre St Katharine's Way, London E1W 1LD 21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient For Registration
More informationThe Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia
VASCULAR CELL OPEN ACCESS ORIGINAL RESEARCH The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia Pagliuso Julia, Parry Suzanne, Haffajee Zenobia, Badrick Tony, Miller Keith,
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationBreast cancer: Antibody selection, protocol optimzation controls and EQA
Breast cancer: Antibody selection, protocol optimzation controls and EQA Workshop in Diagnostic Immunohistochemistry Oud St. Jan/ Old St. John Brugge (Bruges), Belgium June 13th 15nd 2018 Rasmus Røge,
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationStrengths and Weaknesses of PD-L1 testing: Pathology perspective
Strengths and Weaknesses of PD-L1 testing: Pathology perspective Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Foresterhill, Aberdeen Disclosures
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationHPV/p16 Analyte Control
HPV/p16 Analyte Control Utility review and ring study results Colin Tristram, Director 2017 HPV/p16 Analyte Control Collaboration: Dr Max Robinson at Newcastle University a leading pathologist in head
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationUCL-Advanced Diagnostics. 2015/16 Service Update
UCL-Advanced Diagnostics 2015/16 Service Update About UCL-Advanced Diagnostics UCL Advanced Diagnostics (UCL-AD) is the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationHSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationImmunocytochemistry. Run 116/45. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images
Run 116/45 Articles / Reports PD-L1 Pre-Pilot Meeting Report 1-16 Immunocytochemistry Modules General Pathology: Ki67 & E-Cadherin 18-26 Breast Pathology: ER 27-33 Breast Pathology: HER2 IHC 34-4 Gastric:
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationGLOBAL REGISTRATION STRATEGIES:
GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationImmunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images
g Run 119/48 Immunocytochemistry Modules General Pathology: TTF-1& p63 2-11 Breast Pathology: PR 12-19 Breast Pathology: HER2 IHC 2-26 Immunocytochemistry Improving Immunocytochemistry for Over 25 Years
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationQuality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne
Quality control of PD-L1 in NSCLC - Results of two German ring trials 2017-06-07 Dr. Andreas Scheel University Hospital Cologne Step-wise approach Predictive value Biological significance Technical aspects
More informationOptimization of antibodies, selection, protocols and controls Breast tumours
Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin
More informationCompanion & Complementary Diagnostics: Clinical and Regulatory Perspectives
Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives Workshop on Companion Diagnostics January 31, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute Fredensborg, Denmark
More informationLearning from the Impact of the Drug-Diagnostics Strategy in Oncology
Learning from the Impact of the Drug-Diagnostics Strategy in Oncology Critical Path to TB Drug Regimens 2017 Workshop Washington DC March 22, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute
More informationExternal Quality Assessment of Breast Marker Analysis. NordiQC data
External Quality Assessment of Breast Marker Analysis NordiQC data Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Aalborg 12.06 2015 Markers assessed in NordiQC Predictive markers
More informationImage analysis in IHC overview, considerations and applications
Image analysis in IHC overview, considerations and applications Rasmus Røge, MD, Institute of Pathology, Aalborg University Hospital NordiQC workshop September 2016 Aalborg, Denmark Outline Theory Image
More informationTITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma
TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Ms Amy Newman, Ms Suzanne Parry, Mrs Dawn Wilkinson, Dr Tony O Grady, Dr Perry Maxwell, Mr David
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationImmunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images
g Run 113/42 Articles / Reports Scheme Updates: May 216 2 Immunocytochemistry Modules General Pathology: SMA & CK 5/6 3-13 Breast Pathology: ER 14-2 Breast Pathology: HER2 IHC 21-26 Immunocytochemistry
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationNSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA
Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationCorporate presentatie Maastricht UMC+ (titel presentatie)
Datum Corporate presentatie Maastricht UMC+ (titel presentatie) PDL1: een simpele kleuring? Titel Naam spreker van (optioneel) de presentatie Functie spreker (optioneel) Onderwerpregel Ernst Jan M. Speel,
More informationThe innovative aspects are that the test automatically generates a report on ALK status that any clinician can interpret.
pat hways HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer Medtech innovation briefing Published: 7 November 2017 nice.org.uk/guidance/mib128 Summary The technology described
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationOverview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories
Overview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories Dr. Nils t Hart University Medical Center Groningen, The Netherlands Drs. Cleo Keppens Catholic University of Leuven, Belgium
More informationImmunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images
g Run 12/49 UK NEQAS ICC & ISH 218: Autumn Conference. Tower Hotel Immunocytochemistry Modules General Pathology: CD45 & CD56 2-11 Breast Pathology: ER 12-2 Breast Pathology: HER2 IHC 21-28 1 Immunocytochemistry
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationQuality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK)
Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK) 10 Product Codes: HCL007, HCL008 and HCL009 HCL010, HCL011 and HCL012 Page 1 of Contents 1. What is ALK?...
More informationEmerging biomarkers for immunotherapy in lung cancer
Emerging biomarkers for immunotherapy in lung cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Aberdeen, UK Why Do We Need Biomarkers for Immunotherapy?
More informationQuality Assurance in Immunohistochemistry: Experiences from NordiQC
Nordic immunohistochemical Quality Control 2 Quality Assurance in Immunohistochemistry: Experiences from NordiQC Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg University Hospital Aalborg,
More informationAssessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
More informationInterpretation Guide. Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB. Page 1 of 9
Interpretation Guide Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB ALK2/CS/CB_IG_V_001 www.histocyte.com Page 1 of 9 Contents 1. What is ALK?... 2 2. Role of ALK in Cancer...
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationONCO TEAM DIAGNOSTIC
ONCO TEAM DIAGNOSTIC ONCO TEAM SPECIALISTS The team at ONCO TEAM has 23 specialists: o 11 general pathology seniors: - 8 PhD (1 PhD on lung tumors pathology) o 3 general pathology specialists; o 2 dermopathology
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationSMH (Myosin, smooth muscle heavy chain)
Material The slide to be stained for SMH comprised: Assessment Run 50 2017 SMH (Myosin, smooth muscle heavy chain) 1.Tonsil, 2. Esophagus, 3. Breast hyperplasia, 4. Breast ductal carcinoma in situ (DCIS),
More informationBiomarkers for Cancer Immunotherapy Debate
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
More informationInnovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1
Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1 Monday, October 17, 2016 MaRS Discovery District, Toronto This session was generously sponsored by Merck Canada
More informationImmunocytochemistry. Run 106/35. Also In This Issue IN THIS ISSUE
Run 16/35 IN THIS ISSUE Articles / Reports Scheme Updates July 214 2-3 Review of Neuropathology EQA Year: 213-214 The Management of Uncertainty: Increasing Stringency for Validation and Verification of
More informationPD-L1 Testing German Experience. P. Schirmacher for QuIP
PD-L1 Testing German Experience P. Schirmacher for QuIP Quality Management Molecular Diagnostics Method/Inter-Center-Optimisation/Validation Preclinical Validation/internal QM Accreditation Institutes
More informationAssessment Run B HER-2
Assessment Run B1 2006 HER-2 The slide to be stained for HER-2 comprised: 1. Cell line JIMT-1 (Amplified)* 2. Cell line MDA-453 (Amplified) 3. Cell line MCF-7 (Not amplified) 4. Cell line BT474 (Amplified)
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More information10 years of NordiQC Why are 30% of labs still getting it wrong?
Mogens Vyberg & Søren Nielsen NordiQC Institute of Pathology Aalborg University Hospital Aalborg, Denmark May 29th 2015 10 years of NordiQC Why are 30% of labs still getting it wrong? Nothing to declare
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More informationLung Anaplastic Lymphoma Kinase (lu-alk)
Assessment Run 5 207 Lung Anaplastic Lymphoma Kinase (lu-alk) Material The slide to be stained for lu-alk comprised:. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma with
More informationHistoCyte Laboratories Ltd
HistoCyte Laboratories Ltd Progesterone Receptor: The neglected breast receptor! Dr Ian Milton & Colin Tristram November 2018 UKNEQAS Autumn meeting Introduction Progesterone is an important prognostic
More informationThyroid transcription factor-1 (TTF1) Assessment run
Thyroid transcription factor- (TTF) Assessment run 39 203 The slide to be stained for TTF comprised:. Thyroid gland, 2. Liver, 3. Normal lung, 4. Lung adenocarcinoma 5. Colon adenocarcinoma, 6 & 7. Lung
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationVENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody. ALK IHC Biomarker Testing Aiding in patient diagnosis
VENTANA (D5F3) Rabbit Monoclonal Primary Antibody IHC Biomarker Testing Aiding in patient diagnosis 2 IHC Biomarker Testing Lung cancer is the leading cause of death Lung cancer is the most prevalent form
More informationStephen Finn University of Dublin Trinity College and St. James s Hospital, Dublin, Ireland
Evaluation of NGS and other methods for ALK translocation detection in NSCLC patients in Europe: results of the European Thoracic Oncology Platform (ETOP) Lungscape Project Stephen Finn University of Dublin
More informationThe impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
More informationGuideline for the Diagnosis of Breast Cancer
Guideline for the Diagnosis of Breast Cancer Version History Version Date Brief Summary of Change Issued 2.0 May 2007 Approved by the Governance Committee 2.0 25.11.08 Discussed at the NSSG 2.1 5.12.08
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationAnti-hTERT Antibody (SCD-A7)
Quality in Control Anti-hTERT Antibody (SCD-A7) htert_ab_pi_v1 Product Code: HCL025 Contents htert and Telomerase 2 Negative htert 3 Positive htert 4 Guidance and additional data 5 Case Study: RMH12-001
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationIHC Stainer platforms. Overview, pros and cons
IHC Stainer platforms Overview, pros and cons Bart De Wiest Quality manager IHC OLV Hospital, Aalst, Belgium Donald Van Hecke Lab & Quality manager AZ St-Lucas, Brugge, Belgium Goal of this lecture: to
More informationHER2 ISH (BRISH or FISH)
Assessment Run H14 2018 HER2 ISH (BRISH or FISH) Material Table 1. Content of the multi-block used for the NordiQC HER2 ISH assessment, run H14 HER2 IHC* IHC score Dual - SISH** FISH*** FISH*** HER2/chr17
More informationThe following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.
Disclaimer: The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details. These slides are proprietary and should not
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationIdentifying ALK+ NSCLC patients for targeted treatment
VENTANA (D5F3) CDx Assay Identifying + NSCLC patients for targeted treatment VENTANA (D5F3) CDx Assay Identify + NSCLC patients eligible for treatment with XORI, ZYKADIA or ALECENSA NSCLC tissue samples
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationThe unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA
The unknown primary tumour: IHC classification part I, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark the primary panel - Antibody selection,
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationNordiQC - update
NordiQC - update 00-0 EQUALIS Uppsala 0 Tomas Seidal NordiQC participants NordiQC participants n:30 S DK N 6 F Ice Bel 54 NL 4 Ger 6 Aust USA 0 It 8 Argent 8.. 96% participation in S,DK & N ~ 60% in Finland
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationUniversity of Groningen
University of Groningen The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non- Small Cell Lung Cancer Tembuyser, Lien; Tack, Veronique; Zwaenepoel, Karen; Pauwels, Patrick;
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationAbstract. Anatomic Pathology / HER2 Gene Amplification in Breast Cancer
Anatomic Pathology / HER2 Gene Amplification in Breast Cancer HER2 Gene Amplification in Breast Cancer A Rogues Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationSal-like protein 4 (SALL4)
Assessment Run 43 205 Sal-like protein 4 (SALL4) The slide to be stained for SALL4 comprised:. Appendix, 2. Testis, 3. Renal clear cell carcinoma, 4. Seminoma, 5. Intratubular germ cell neoplasia (IGCN),
More information